Alessandro Pastore Selected Research

vadastuximab talirine

1/2019

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Pastore Research Topics

Disease

16	Neoplasms (Cancer) 01/2022 - 09/2004
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2016
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2012 - 03/2009
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020 - 09/2015
2	Lymphoma (Lymphomas) 01/2020 - 01/2017
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 01/2016
2	Leukemia 01/2016 - 01/2016
1	Histiocytosis 12/2019
1	Carcinogenesis 10/2019
1	Lymphocytosis 01/2019
1	Inflammation (Inflammations) 10/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Gliosis 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Leukostasis 01/2014
1	Heart Diseases (Heart Disease) 02/2013
1	Cardiotoxicity 02/2013
1	Hyperthermia 06/2009
1	Multiple Sclerosis 05/2002

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 10/2019 - 03/2009
3	RNA Splicing FactorsIBA 10/2019 - 01/2016
3	Proteasome InhibitorsIBA 06/2012 - 03/2009
3	Bortezomib (Velcade)FDA Link 06/2012 - 03/2009
2	MicroRNAs (MicroRNA)IBA 01/2020 - 11/2009
2	CytokinesIBA 01/2020 - 10/2018
2	Phosphotransferases (Kinase)IBA 12/2019 - 01/2017
2	ibrutinibIBA 01/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 09/2004
1	Immune Checkpoint InhibitorsIBA 01/2022
1	CytosineIBA 10/2020
1	cathepsin SIBA 01/2020
1	AntigensIBA 01/2020
1	CrizotinibIBA 12/2019
1	selpercatinibIBA 12/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2019
1	tyrosine receptor (receptor, tyrosine)IBA 12/2019
1	Pharmaceutical PreparationsIBA 10/2019
1	Nuclear Export Signals (Nuclear Export Signal)IBA 10/2019
1	Histones (Histone)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	vadastuximab talirineIBA 01/2019
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	ChemokinesIBA 10/2018
1	Biological ProductsIBA 01/2018
1	Estrogens (Estrogen)FDA Link 01/2018
1	Hormones (Hormone)IBA 01/2018
1	LigandsIBA 01/2018
1	MethyltransferasesIBA 01/2018
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018
1	Estrogen Receptor alphaIBA 01/2018
1	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 01/2017
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2017
1	Amyloid (Amyloid Fibrils)IBA 01/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2015
1	Prednisone (Sone)FDA LinkGeneric 09/2015
1	Rituximab (Mabthera)FDA Link 09/2015
1	Vincristine (Oncovin)FDA LinkGeneric 09/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2015
1	AnthracyclinesIBA 02/2013
1	Biomarkers (Surrogate Marker)IBA 02/2013
1	ATP dependent 26S protease (26S proteasome)IBA 06/2012
1	3' Untranslated Regions (3' UTR)IBA 11/2009
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2009
1	Cyclin D1IBA 11/2009
1	Annexin A5IBA 06/2009
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2009
1	Proteasome Endopeptidase Complex (Proteasome)IBA 03/2009
1	NucleotidesIBA 05/2002
1	Myelin-Associated GlycoproteinIBA 05/2002

Therapy/Procedure

3	Therapeutics 01/2019 - 01/2014
1	Immunotherapy 01/2022
1	Aftercare (After-Treatment) 01/2019
1	Blood Component Removal (Apheresis) 01/2014